سعر ميكوفينولات للاطفال حقن وريدي 2022

Mycophenolate mofetil (Accord) powder for intravenous infusion; antimetabolite immunosuppressant for prophylaxis of organ transplant rejection (vial strength not stated by the Egyptian source).

• Prophylaxis of organ rejection in adult recipients of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants; the IV form is an alternative when oral medication cannot be tolerated.Population: Adults (IV)DailyMed (U.S. National Library of Medicine)

• Hypersensitivity (including anaphylaxis) to mycophenolate mofetil, mycophenolic acid or any component; the US IV product is also contraindicated in patients allergic to polysorbate 80 (an excipient of CELLCEPT Intravenous).General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Boxed warning: use during pregnancy is associated with increased risks of first-trimester pregnancy loss and congenital malformations; avoid if safer options exist and counsel females of reproductive potential on pregnancy prevention and planning. Increased risk of lymphoma and other malignancies, particularly of the skin. Increased susceptibility to bacterial, viral, fungal and protozoal infections, including opportunistic infections and viral reactivation of hepatitis B and C, which may lead to hospitalisation and death.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Monitor for blood dyscrasias (neutropenia, pure red cell aplasia) and interrupt or reduce the dose if they occur; risk of serious GI complications (bleeding, ulceration, perforation); avoid in hereditary HGPRT deficiency; acute inflammatory syndrome and hypersensitivity reactions possible; avoid live attenuated vaccines; no blood donation during therapy and for 6 weeks after, no semen donation during therapy and for 90 days after.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Antacids containing magnesium or aluminium hydroxideDecrease MPA systemic exposure and may reduce efficacy; give these antacids at least 2 hours after mycophenolate mofetil.DailyMed (U.S. National Library of Medicine)
• Proton pump inhibitors (e.g. lansoprazole, pantoprazole)Decrease MPA exposure; monitor for altered efficacy.DailyMed (U.S. National Library of Medicine)
• Drugs interfering with enterohepatic recirculation (e.g. ciclosporin, trimethoprim/sulfamethoxazole, cholestyramine, rifampin, some antibiotics)May decrease MPA exposure; monitor for altered efficacy or adverse reactions.DailyMed (U.S. National Library of Medicine)

• Mycophenolate use in pregnancy is associated with increased first-trimester pregnancy loss and multiple congenital malformations (e.g. external ear and facial abnormalities including cleft lip and palate, distal limb, heart, oesophagus, kidney and nervous system anomalies); consider alternative immunosuppressants with less embryofetal toxicity.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• No data on mycophenolate in human milk; MPA is present in rat milk; only limited registry data on breastfed infants are available; potential infant risk cannot be excluded, so weigh breastfeeding benefits against the mother's need for therapy.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Mycophenolate mofetil: Prodrug rapidly hydrolysed to mycophenolic acid (MPA), a selective uncompetitive inhibitor of inosine monophosphate dehydrogenase (IMPDH) that blocks de novo guanosine nucleotide synthesis and lymphocyte proliferation (US CELLCEPT label).